Patrick Friedli, MD
Family Medicine · Traverse City, MINPI 1255341046
Payments from drug & device makers
Across 268 payments — averaging $18.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$821
- Novo Nordisk$647
- AstraZeneca$592
- AbbVie$448
- Pfizer$293
- Astellas Pharma US Inc$263
- plus $2K from 33 others
What the payments were for
- Food & beverage$4,93898%
- Education$1152%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 73 | $821 |
| Novo Nordisk | 8 | $647 |
| AstraZeneca | 24 | $592 |
| AbbVie(2 entities) | 24 | $448 |
| Pfizer | 10 | $293 |
| Astellas Pharma US Inc | 6 | $263 |
| Supernus Pharmaceuticals, Inc. | 15 | $214 |
| Boehringer Ingelheim | 10 | $193 |
| Lilly USA, LLC | 11 | $188 |
| Amgen(2 entities) | 11 | $180 |
| Merck | 10 | $150 |
| Johnson & Johnson | 8 | $128 |
| Novartis | 7 | $115 |
| Sunovion Pharmaceuticals Inc. | 7 | $64 |
| Dexcom, Inc. | 3 | $61 |
| Bayer | 3 | $57 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $57 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $57 |
| Sanofi-aventis U.S. LLC | 3 | $48 |
| E.r. Squibb & Sons, L.L.C. | 3 | $45 |
| Sanofi Pasteur Inc. | 3 | $43 |
| Verona Pharma, Inc. | 2 | $42 |
| Alphatec Spine, Inc | 1 | $38 |
| Eisai Inc. | 2 | $34 |
| Ironshore Pharmaceuticals Inc. | 2 | $27 |
| Boston Scientific | 1 | $27 |
| Biogen | 2 | $25 |
| Axsome Therapeutics, Inc. | 1 | $22 |
| Amarin Pharma, Inc. | 1 | $22 |
| Esperion Therapeutics, Inc. | 1 | $18 |
| Neos Therapeutics, LP | 1 | $17 |
| Tris Pharma Inc | 1 | $17 |
| Xeris Pharmaceuticals, Inc. | 1 | $17 |
| Otsuka America Pharmaceutical, Inc. | 1 | $16 |
| Exact Sciences | 1 | $15 |
| UCB, Inc. | 1 | $14 |
| Mylan Specialty L.p. | 1 | $14 |
| Teva Pharmaceuticals USA, Inc. | 1 | $13 |
| Kowa Pharmaceuticals America, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,053 in reported general payments places this provider in the 90th percentile of 3,945 family medicine providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 87 | $114,336 |
| TrulicityDulaglutide | 63 | $99,847 |
| FarxigaDapagliflozin Propanediol | 74 | $98,118 |
| MounjaroTirzepatide | 87 | $97,418 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 119 | $96,456 |
| JardianceEmpagliflozin | 74 | $85,748 |
| MyrbetriqMirabegron | 41 | $33,178 |
| XareltoRivaroxaban | 21 | $21,666 |
| JanuviaSitagliptin Phosphate | 24 | $19,871 |
| VraylarCariprazine Hcl | 15 | $19,398 |
| GlyxambiEmpagliflozin/Linagliptin | 22 | $18,891 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 30 | $16,236 |
| Repatha SyringeEvolocumab | 19 | $10,225 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 20 | $10,065 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 15 | $9,241 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCTrulicity, Mounjaro | $188 | $197,265150 claims |
| Boehringer IngelheimJardiance, Glyxambi, Stiolto Respimat | $193 | $120,875126 claims |
| PfizerEliquis | $293 | $114,33687 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $592 | $107,35989 claims |
| GSKTrelegy Ellipta, Anoro Ellipta | $821 | $106,521139 claims |
| Astellas Pharma US IncMyrbetriq | $263 | $33,17841 claims |
| Johnson & JohnsonXarelto | $128 | $21,66621 claims |
| MerckJanuvia | $150 | $19,87124 claims |
| AbbVieVraylar | $448 | $19,39815 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 3,945 family medicine providers in Michigan.
Other family medicine in Traverse City
- Rafay BaigTraverse City$48K
- Kathryn ShafferTraverse City$20K
- Derrick WilliamsonSouthfield$9.9M
- Rebecca RivardRoseville$7M
- Paul BensonBerkley$4.2M
- Michael HafranEast Lansing$2.7M
- Mitzie HewittBuckley$1.3M
- Loren ChudlerSouthfield$1.3M
- Solomon AmsterWhite Lake$981K
- Matt RosenbergJackson$559K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.